SpCas9, Active (CS09-E311H)

SpCas9, Active (CS09-E311H)

  • $98.00


FOR BULK ORDER REQUESTS PLEASE CONTACT US

Description : Recombinant full-length Streptococcus pyogenes Cas9 was expressed in E. coli with a C-terminal His tag.

Species :Human

Tag : HIS tag

Expression System: E.Coli

Sequence :Full length

Genbank Number : X78809.

Specific Activity : Sample Activity Plot. For specific information on a given lot, see related technical data sheet.

Purity :Sample Purity Data. For specific information on a given lot, see related technical data sheet.



Storage, Stability and Shipping :Store product at –70oC. For optimal storage, aliquot target into smaller quantities after centrifugation and store at recommended temperature. For most favorable performance, avoid repeated handling and multiple freeze/thaw cycles.

Molecular Weight :~156 kDa

Gene Aliases : Cas9, Csn1, Spy_1046

Scientific Background : Streptococcus pyogenes Cas9 is a type II-A Cas9 protein and is the most used in most current CRISPR-based genetic engineering methodologies (1). CRIPSR RNAs (crRNAs) fused to trans-activating CRISPR RNAs (tracrRNA) direct sequence-specific cleavage by Cas9, introducing double-stranded breaks in cell-invading DNA in bacterial and archaeal CRIPSR/Cas9 systems (1,2). Cas9 requires the 5’-NGG-3’ protospacer adjacent motif (PAM) to destabilize the target DNA (3). Cas9’s HNH endonuclease domain cleaves the strand complementary to the crRNA while its RuvC endonuclease domain cleaves the non-complementary strand (2).

References :

  1. Jinek, M. et al. Structures of Cas9 Endonucleases Reveal RNA-Mediated Conformational Activation. Science. 2014, 343(6176): 1247997.
  2. Jinek, M. et al. A programmable dual RNA-guided endonuclease in adaptive bacterial immunity. Science. 2012, 337(6096): 816-821.
  3. Anders, C. et al. Structural basis of PAM-dependent target DNA recognition by the Cas9 endonuclease. Nature. 2014, 513(7519): 569-573.

Product Sheets (By Lot #) :

T4216-7

 

Research Areas :Cancer, Receptor Tyrosine Kinases, Ser/Thr Kinases, Cancer, Ser/Thr Kinases